a structural analogue of DA, has potential advantages over DA because it has
(arrhythmogenic) and α-adrenergiceffects.
Because of the decreased β-adrenergic
effects and its specific effect on renal perfusion, it may have advantages over
dobutamine. The drug has been clinically available in many countries since
1990, but has not gained widespread acceptance in practice.
Dopexamine infusion should be started at
a rate of 0.5 mcg/kg/min, increasing to 1 mcg/kg/min at intervals of 10–15 min
to a maximum infusion rate of 6 mcg/kg/min.